Roivant (ROIV) Climbs 15% on Swing to Profits

Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the 10 Stocks With Insane Returns Right Now.

Roivant Sciences grew its share prices by 14.89 percent on Wednesday to close at $32.41 apiece, as investors took heart from its swing to profitability in the fourth quarter of fiscal year 2026, while positioning portfolios ahead of the launch of its autoimmune disease treatment.

In an updated report, Roivant Sciences Ltd. (NASDAQ:ROIV) said that it swung to an attributable net income of $302.99 million from a $206.47 million attributable net loss in the same period last year, thanks to a $415 million operating income, which reversed a $284.96 million operating loss in the same period.

For illustration purposes only. Photo by Gustavo Fring on Pexels

Revenues, on the other hand, fell by 66.7 percent to $2.52 million from $7.57 million in the same quarter last year.

Looking ahead, Roivant Sciences Ltd. (NASDAQ:ROIV) is targeting to commercially launch by the end of September its oral treatment, brepocitinib, to treat severe and rare autoimmune conditions.

Roivant Sciences Ltd. (NASDAQ:ROIV) said that the Food and Drug Administration has officially accepted its new drug application for the therapy, with an assigned target action date in the third quarter of the year.

While we acknowledge the potential of ROIV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.